Patent ID: 11866499
Assignee: JANSSEN BIOTECH, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 16:
17. A method of producing the bispecific anti-TMEFF2/anti-CD3 antibody or the antigen binding fragment thereof of claim 1, comprising:
combining a monospecific bivalent TMEFF2 antibody having two identical HC1 and two identical LC1 and a monospecific bivalent CD3 antibody having two identical HC2 and two identical LC2 in a mixture of about 1:1 molar ratio;
introducing a reducing agent into the mixture;
incubating the mixture comprising the reducing agent for about ninety minutes to about six hours;
removing the reducing agent after said incubating step; and
purifying the bispecific anti-TMEFF2/anti-CD3 antibody or an antigen binding fragment thereof that comprises the HC1, the LC1, the HC2 and the LC2 after the reducing agent has been removed,
wherein the HC1 and LC1 comprises a HCDR1, a HCDR2, a HCDR3, a LCDR1, a LCDR2, and a LCDR3 of SEQ ID NOs: 10, 12, 15, 18, 20, and 86, respectively, and the HC2 and LC2 comprises a HCDR1, a HCDR2, a HCDR3, a LCDR1, a LCDR2, and a LCDR3 of SEQ ID NOs: 68, 69, 70, 71, 72, and 73, respectively.